Literature DB >> 17576548

Relationship between methadone and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) in urine samples from Norwegian prisons.

Jean-Paul Bernard1, Mimi Stokke Opdal, Ritva Karinen, Jørg Mørland, Hassan Z Khiabani.   

Abstract

BACKGROUND: Methadone maintenance treatment is a widely used therapy in the rehabilitation of opioid addiction the world over. Methadone is metabolised in the body to a number of inactive metabolites, but primarily to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). The Division of Forensic Toxicology and Drug Abuse (DFTDA) of the Norwegian Institute of Public Health carries out drug analysis of urine samples from inmates of prisons throughout Norway. Methadone and EDDP in the urine are also tested for upon request. The results are stored in a secure database at the DFTDA.
OBJECTIVES: The aims of the present study were (1) to observe variations in methadone and EDDP concentrations in urine in relation to urine pH in a large set of urine samples obtained from prison inmates and (2) to analyse samples testing methadone-positive/EDDP-negative and investigate whether such results could occur naturally, without sample tampering.
METHODS: All urine samples that tested positive for methadone over the period 2004-2005 were collected from the DFTDA database, and the relation between methadone and EDDP excretion in urine, and urinary pH was determined. Samples that tested positive for methadone but negative for EDDP were picked out and studied individually.
RESULTS: A total of 1539 urine samples (cases) had tested positive for methadone in our database for the period 2004-2005. There was a strong correlation between the concentration of methadone in urine and urine pH in these samples, with higher concentrations of methadone present at lower pH levels. Cases that tested positive for methadone but negative for EDDP were rare - a total of five (0.3% of all cases tested). These cases were studied in more detail.
CONCLUSION: Methadone excretion in urine is dependent on urinary pH. Methadone-positive/EDDP-negative results may suggest sample tampering in some, but not all, cases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576548     DOI: 10.1007/s00228-007-0314-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Opioid abuse and cognitive performance.

Authors:  Miriam Z Mintzer; Marc L Copersino; Maxine L Stitzer
Journal:  Drug Alcohol Depend       Date:  2004-12-10       Impact factor: 4.492

2.  Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.

Authors:  Alexander N Katchman; Kelly A McGroary; Michael J Kilborn; Craig A Kornick; Paolo L Manfredi; Raymond L Woosley; Steven N Ebert
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

3.  A pilot study to determine the usefulness of the urinary excretion of methadone and its primary metabolite (EDDP) as potential markers of compliance in methadone detoxification programs.

Authors:  S George; R A Braithwaite
Journal:  J Anal Toxicol       Date:  1999 Mar-Apr       Impact factor: 3.367

4.  Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses.

Authors:  G D Bellward; P M Warren; W Howald; J E Axelson; F S Abbott
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

5.  Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.

Authors:  Y Oda; E D Kharasch
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

6.  Application and validation of a urinary methadone metabolite (EDDP) immunoassay to monitor methadone compliance.

Authors:  S George; S Parmar; C Meadway; R A Braithwaite
Journal:  Ann Clin Biochem       Date:  2000-05       Impact factor: 2.057

7.  Cognitive impairment among methadone maintenance patients.

Authors:  S Darke; J Sims; S McDonald; W Wickes
Journal:  Addiction       Date:  2000-05       Impact factor: 6.526

8.  QTc interval prolongation in patients on long-term methadone maintenance therapy.

Authors:  Icro Maremmani; Matteo Pacini; Claudio Cesaroni; Mercedes Lovrecic; Giulio Perugi; Alessandro Tagliamonte
Journal:  Eur Addict Res       Date:  2005       Impact factor: 3.015

9.  QTc interval prolongation associated with intravenous methadone.

Authors:  Craig A Kornick; Michael J Kilborn; Juan Santiago-Palma; Glenn Schulman; Howard T Thaler; Deborah L Keefe; Alexander N Katchman; John C Pezzullo; Steven N Ebert; Raymond L Woosley; Richard Payne; Paolo L Manfredi
Journal:  Pain       Date:  2003-10       Impact factor: 6.961

10.  Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.

Authors:  Julia Kirchheiner; Gunnar Müller; Ingolf Meineke; Klaus-Dieter Wernecke; Ivar Roots; Jürgen Brockmöller
Journal:  J Clin Psychopharmacol       Date:  2003-10       Impact factor: 3.153

View more
  2 in total

Review 1.  Nephrotoxicity of methadone: a systematic review.

Authors:  Samira Alinejad; Kazem Ghaemi; Mohammad Abdollahi; Omid Mehrpour
Journal:  Springerplus       Date:  2016-12-09

2.  Methadone Concentrations in Exhaled Breath Condensate, Serum and Urine of Patients Under Maintenance Treatment.

Authors:  Maryam Khoubnasabjafari; Khalil Ansarin; Vahid Jouyban-Gharamaleki; Vahid Panahi-Azar; Samin Hamidi; Zhila Azarmir; Abolghasem Jouyban
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.